Sepsis remains one of the most urgent clinical emergencies in modern healthcare. Each hour of delayed targeted treatment significantly increases patient mortality. For decades, intensive care and emergency clinicians have struggled with the critical challenge of distinguishing sepsis from non-infectious systemic inflammation. Conventional culture tests take days, and traditional inflammatory markers frequently fail to deliver the precision clinicians need at the bedside.
Immunexpress is tackling this diagnostic dilemma with SeptiCyte RAPID, a molecular test that measures the patient’s own immune response to detect sepsis in about an hour. Leading this clinical mission is Chief Medical Officer Dr Roy Davis, whose decades of leadership span neonatal critical care, health system quality, and early warning algorithms. In this executive Q&A, Dr Davis shares his clinical perspective on modern sepsis management, the diagnostic power of host-response technology, and how rapid testing empowers physicians to make timely, confident decisions.
Q: Sepsis diagnosis has historically relied on non-specific inflammatory markers and slow blood cultures. How does measuring the host immune response fundamentally change this diagnostic process?
Dr Roy Davis:
Q: Clinicians in the ICU frequently struggle to distinguish between non-infectious systemic inflammation and active sepsis. How does SeptiCyte RAPID help resolve that uncertainty early in patient care?
Dr Roy Davis:
Q: Earlier in your career, you pioneered electronic surveillance algorithms and early warning tools. How does a molecular test like SeptiCyte RAPID integrate with and enhance hospital surveillance protocols?
Dr Roy Davis:
Q: Sepsis presentations vary widely across vulnerable groups, including neonates, oncology patients, and the immunocompromised. How robust is host-response diagnostic accuracy across these complex populations?
Dr Roy Davis:
Q: From your background in hospital administration and quality improvement, what operational and economic advantages does rapid sepsis discrimination bring to a health system?
Dr Roy Davis:
Q: Looking at hospital-wide diagnostic pathways, how does the ability to produce a reliable sepsis score in about an hour reshape current antimicrobial stewardship practices?
Dr Roy Davis:
Rapid diagnostic precision is essential to reduce sepsis mortality and optimize critical care resources. By reading the patient’s specific genomic immune response rather than waiting for pathogen growth, clinicians can differentiate sepsis from sterile inflammation in critical early hours. This proactive clarity allows medical teams to deliver life-saving interventions immediately while avoiding unnecessary broad-spectrum antibiotic use.
As health systems face rising patient acuity and operational pressures, integrating fast host-response diagnostics like SeptiCyte RAPID will redefine emergency and intensive care workflows. Transitioning from reactive detection to rapid host-directed insight protects vital hospital resources and safeguards patient outcomes. With proven clinical validation and accelerated turnaround times, Immunexpress provides the clinical standard needed to stop sepsis in its tracks.
To learn more, visit https://immunexpress.com/